Increase of the therapeutic effect on non-small‑cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro

  • Authors:
    • Ying Chen
    • Yong Cao
    • Danlei Yang
    • Kaiyan Li
    • Zhengyun Wang
    • Jing Zhu
    • Hansvin Bunjhoo
    • Shengdao Xiong
    • Yongjian Xu
    • Weining Xiong
  • View Affiliations

  • Published online on: November 16, 2011     https://doi.org/10.3892/etm.2011.381
  • Pages: 255-260
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Overexpression of Cyclin D1 and Bcl-xL proteins has often been found in non-small-cell lung cancer (NSCLC). These two genes may play a significant role in tumorigenesis. However, the combined inhibition of the two genes in vitro is unclear in NSCLC. In this study, the effect of a combined intervention on Cyclin D1 and Bcl-xL in NSCLC is assessed and discussed. Three recombinant plasmids that expressed a cytomegalovirus (CMV) promoter-driven micro30 short hairpin RNA (shRNA) targeting the Cyclin D1 gene (Cyclin D1 shRNA), the Bcl-xL gene (Bcl-xL shRNA) and a combination of the two genes (Cyclin D1-Bcl-xL shRNA), based on the plasmid pcDNA6.2‑GW/EmGFP-miR, were constructed. The cell lines A549 and NCI-H441 were divided into four groups; blank control (untreated cells), Cyclin D1 shRNA, Bcl-xL shRNA and Cyclin D1-Bcl-xL shRNA (transfected cells), respectively. The expression of mRNA and protein of Cyclin D1 or Bcl-xL was detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting, respectively. The apoptosis and proliferation of the two cell lines were evaluated by dimethylthiazol-diphenyltetrazolium bromide (MTT), cell count and flow cytometry. The recombinant plasmid sufficiently mediated the RNA interference (RNAi) effects in A549 and NCI-H441 cells. The expression levels of mRNA and protein of Cyclin D1 or Bcl-xL in the three intervention groups were significantly reduced compared to the untreated cells (P<0.05). No statistical differences were found among the combined shRNAs and single shRNA regarding Cyclin D1 or Bcl-xL, respectively (P>0.05). In the assessment of proliferation and apoptosis, it was found that in all three intervention groups there was significant inhibition of cell proliferation and promotion of cell apoptosis compared with the untreated cells (P<0.05). Furthermore, the combined interference of the two genes was more effective than either single interference (P<0.05). Our results suggested that the combined targeting of Cyclin D1 and Bcl-xL genes has potential for NSCLC investigation, providing increased efficacy over Cyclin D1 or Bcl-xL inhibition alone.
View Figures
View References

Related Articles

Journal Cover

February 2012
Volume 3 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Cao Y, Yang D, Li K, Wang Z, Zhu J, Bunjhoo H, Xiong S, Xu Y, Xiong W, Xiong W, et al: Increase of the therapeutic effect on non-small‑cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro. Exp Ther Med 3: 255-260, 2012.
APA
Chen, Y., Cao, Y., Yang, D., Li, K., Wang, Z., Zhu, J. ... Xiong, W. (2012). Increase of the therapeutic effect on non-small‑cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro. Experimental and Therapeutic Medicine, 3, 255-260. https://doi.org/10.3892/etm.2011.381
MLA
Chen, Y., Cao, Y., Yang, D., Li, K., Wang, Z., Zhu, J., Bunjhoo, H., Xiong, S., Xu, Y., Xiong, W."Increase of the therapeutic effect on non-small‑cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro". Experimental and Therapeutic Medicine 3.2 (2012): 255-260.
Chicago
Chen, Y., Cao, Y., Yang, D., Li, K., Wang, Z., Zhu, J., Bunjhoo, H., Xiong, S., Xu, Y., Xiong, W."Increase of the therapeutic effect on non-small‑cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro". Experimental and Therapeutic Medicine 3, no. 2 (2012): 255-260. https://doi.org/10.3892/etm.2011.381